Sculptra and Botox Cosmetic run on completely different clocks, and neither one does what the other does. Botox Cosmetic works within days, peaks at about two weeks and wears off. Sculptra shows almost nothing on the day, builds over a course of sessions across months, and has been measured out to two years and beyond.
Sculptra is poly-L-lactic acid, or PLLA — tiny particles of a biodegradable polymer supplied as a freeze-dried cake and mixed with sterile water before injection. The fluid is absorbed within days. What remains is a scaffold of particles that provokes a low-grade response from the body, and fibroblasts lay down new collagen around them. The particles break down into lactic acid, which the body handles through normal metabolism.
Botox Cosmetic is onabotulinumtoxinA. It blocks acetylcholine release at the nerve ending so the injected muscle stops contracting fully. It adds no volume, builds no collagen and leaves nothing behind.
Sculptra cannot smooth a frown line caused by muscle movement. Botox Cosmetic cannot replace lost volume. No trial has compared them, and none could — this is the least overlapping pair in the whole toxin-versus-filler question.
Approved as a Class III device through the FDA's premarket approval route, PMA P030050.
The volume you end up with is your own tissue. The polymer itself is gone within a couple of years.
The label regimen runs to four sessions about three weeks apart, so the result accumulates across the course and the months after it.
The 2009 approval was based on up to four injection sessions at about three-week intervals, with a maximum of 2.5 mL per nasolabial fold per session. In the 2023 cheek trial people had a mean of 3.6 sessions.
Label doses, in Botox Cosmetic Units only: 20 Units for glabellar lines, 24 Units for lateral canthal lines, 40 Units total for forehead and glabellar lines treated together, and 26, 31 or 36 Units for platysma bands.
In the 2009 nasolabial fold trial, 233 people were randomised against a collagen comparator, the controlled phase ran to month 13, and 95 of the 106 who entered the extension completed month 25 with wrinkle scores that "remained stable or improved". In the 2023 cheek trial, 70.7% of treated people met a one-grade improvement at month 12 against 25.9% of untreated controls, and the previously treated extension group was at 76.9% at months 21 and 24. The FDA's consumer page describes PLLA effects as lasting up to two years.
Published trials measured results at day 30 and day 60; one comparison of three brands followed people for 180 days.
The 2004 approval covers facial fat loss in people with HIV. The 2009 approval covers "shallow to deep nasolabial fold contour deficiencies and other facial wrinkles in which deep dermal grid pattern (cross-hatch) injection technique is appropriate" in immune-competent people. A 2023 approval added fine lines and wrinkles in the cheek region.
Glabellar lines (2002), lateral canthal lines (2013), forehead lines (2017) and platysma bands (2024).
Hyaluronidase breaks down hyaluronic acid. PLLA is a polyester of lactic acid with no target for that enzyme. The Sculptra Aesthetic instructions for use mention no reversal agent at all. The realistic options for an unwanted result are time, saline infiltration with mechanical disruption, corticosteroids and, rarely, surgery.
If you want to look different for an event in three weeks, only one of these is on that timescale: Botox Cosmetic is injected once, works within days and reaches its peak at around two weeks.
Sculptra is the opposite proposition. The fluid it is mixed with is absorbed within days, so any immediate fullness disappears and the treated area looks much as it did. The collagen response builds across a course of about three to four sessions spaced roughly three weeks apart, and the result accrues over the months that follow. The people who are unhappy with Sculptra are very often people who judged it too early.
The other end of the clock differs just as much. Botox Cosmetic wears off as nerve terminals recover, and the treatment is repeated. Sculptra's own trials measured a result that was still there at 24 and 25 months — with the caveat that those are the points where the studies ended, and that the 25-month figure came from a self-selected extension group with no control arm after month 13.
Sculptra will not soften a frown line that only appears when you frown: It builds collagen; it does not switch off a muscle. It is also injected into the deep dermis with a threading technique, which is not how or where a dynamic line is treated.
Botox Cosmetic will not restore a hollow temple or a flat cheek: It occupies no space. Relaxing a muscle in a deflated area does not put anything back.
The approved indications make the same point. Sculptra's cover facial fat loss, nasolabial folds and other facial wrinkles, and cheek fine lines. Botox Cosmetic's cover the glabella, the outer eye, the forehead and the platysma bands of the neck. Those lists do not touch anywhere on the face.
This is where the time difference becomes a risk difference. A hyaluronic acid filler can be dissolved. Sculptra cannot. Hyaluronidase hydrolyses hyaluronic acid and has no enzymatic target in poly-L-lactic acid.
That does not make Sculptra permanent — the particles do break down — but "not permanent" and "not reversible" are different things. If a result is wrong, the options documented in the literature are waiting, saline infiltration with mechanical disruption through a cannula, intralesional corticosteroids, antibiotics where a biofilm is suspected, and surgical excision as a last resort. There is no approved reversal agent.
Sculptra's signature complication is a delayed lump. In the 2009 nasolabial fold trial, nodules or papules were reported in 17.2% of the Sculptra group and 12.8% of the collagen control group. In the 2023 cheek trial, injection-site nodules were reported in 1 of 97 treated subjects analysed, still present at study completion. The label records nodule onset at a median of 160 days and a median duration of 100 days. Those figures come from different trials with different ways of counting and cannot be lined up as a league table.
Botox Cosmetic carries no equivalent problem, because nothing is left in the tissue.
No professional society currently publishes a price for either: The American Society of Plastic Surgeons stopped reporting fees for minimally invasive procedures after 2023. Its last published figure for non-hyaluronic-acid fillers, a category that pools Radiesse, Sculptra, Bellafill and Renuva, was $901 for 2023 — a physician fee only, per procedure, not per vial. Because Sculptra is normally sold as a course of three or four sessions, a single-session figure understates the total. There is no comparable current published figure for Botox Cosmetic.
These signs can mean filler has entered a blood vessel. That is a rare event, and it is a medical emergency where time matters in hours.
Any change in vision — blurring, a dark patch, double vision or loss of sight in one eye, during or straight after an injection
Pain that is far worse than the procedure should cause, or pain that keeps building
Skin that turns white or pale in a patch soon after an injection, then goes dusky, blotchy or net-like
Weakness, drooping, slurred speech or confusion
Published guidance treats suspected blockage of the artery to the eye as a same-hour emergency and suspected skin blockage as a same-day emergency. In a review of 511 published blindness cases from 1906 to 2023, 68.2% of the 318 people with a recorded outcome had no recovery of vision, and no treatment used was significantly associated with improvement. Do not wait to see if it settles, and do not assume pain will warn you — in a survey of 52 experienced injectors, pain was mild or absent in 47% of the blocked-vessel events they described.
Swelling is still growing three or more days after treatment instead of settling
A lump appears and will not settle, or one appears weeks or months later
Redness spreads outward from the injection site, or the area becomes hot and tender
Tenderness, firmness or swelling turns up weeks after treatment, sometimes after an illness, a vaccination or dental work — this is a recognised delayed reaction
The product looks like it has moved out of the area that was treated